Primary small cell carcinoma of the esophagus: review of 64 cases from a single institution.

Primary small cell carcinoma of esophagus (SCCE) is a rare disease with poor prognosis. The aims of this study are to review the clinical characteristics, treatment modalities, and outcomes of SCCE and to investigate the prognostic factors and optimal treatment options. Sixty-four patients diagnosed as SCCE in Sun Yat-sen University Cancer Center from 1990 to 2011 were retrospectively reviewed. There were 46 patients with limited disease (LD) and 18 with extensive disease. The median survival time (MST) and overall survival rate were calculated and compared by the Kaplan-Meier method and log-rank test, respectively. The prognostic factors were calculated by Cox hazards regression model. With a median follow up of 11.6 months, the MST of all the 64 patients was 12.6 months, 16.5 months for LD and 9.0 months for extensive disease. The 1-, 3-, and 5-year overall survivals were 52.5%, 20.9%, and 7.5%, respectively. In univariate analysis, patients with ECOG performance score <2 (P = 0.009), lesion length ≤5 cm (P = 0.009), T stage ≤2 (P = 0.004), LD (P = 0.000), and multimodality treatment (P = 0.016) had significant associations with MST. Multivariate analysis showed that ECOG performance score (P = 0.001), T stage (P = 0.023), limited-extensive stage (P = 0.007), and treatment modality (P = 0.008) were independent prognostic factors. Locoregional treatment combined with chemotherapy had a trend to increase MST from 15.3 to 20.0 months in LD patients (P = 0.126), while combined chemotherapy had a significant impact on MST in extensive disease patients (P = 0.000). SCCE is a highly malignant disease with poor prognosis. Patients might obtain survival benefit from the combination of locoregional treatment and systemic therapy. Prospective studies are needed to validate these factors.

[1]  T. Yano,et al.  Non-surgical approach to small cell carcinoma of the esophagus: does this rare disease have the same tumor behavior as SCLC? , 2012, International Journal of Clinical Oncology.

[2]  P. van Houtte,et al.  Small cell carcinoma of the esophagus: a multicentre Rare Cancer Network study. , 2011, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[3]  Weihua Yang,et al.  Treatment and prognosis of limited disease primary small cell carcinoma of esophagus. , 2011, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[4]  H. Fujita,et al.  Surgical management for small cell carcinoma of the esophagus. , 2010, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[5]  Jie He,et al.  Primary Small Cell Carcinoma of the Esophagus , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  N. Koide,et al.  Clinicopathologic features and histochemical analyses of proliferative activity and angiogenesis in small cell carcinoma of the esophagus , 2007, Journal of Gastroenterology.

[7]  T. Crosby,et al.  Small cell oesophageal carcinoma: an institutional experience and review of the literature , 2007, British Journal of Cancer.

[8]  Laura H. Tang,et al.  Small-cell carcinomas of the gastrointestinal tract: a review. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Kim,et al.  Primary extrapulmonary small cell carcinoma involving the stomach or duodenum or both: findings on CT and barium studies. , 2003, AJR. American journal of roentgenology.

[10]  K. Mori,et al.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.

[11]  N. Akpolat,et al.  Primary Composite Tumour with Bipartite Differentiation of the Esophagus , 2000, Acta chirurgica Belgica.

[12]  J. Ferlay,et al.  Estimates of the worldwide mortality from 25 cancers in 1990 , 1999, International journal of cancer.

[13]  J P Pignon,et al.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. , 1999, The New England journal of medicine.

[14]  B. Farrús,et al.  Primary small cell carcinoma of the esophagus , 1997, Cancer.

[15]  K. Hatakeyama,et al.  Tumor spread and outcome of treatment in primary esophageal small cell carcinoma , 1997, Journal of surgical oncology.

[16]  H. Fujita,et al.  Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. , 1993 .

[17]  L. Johansson,et al.  Small cell carcinoma of the oesophagus: a clinical and immunohistopathological review. , 1990, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  H. Elie,et al.  Autopsy findings in 111 cases of esophageal cancer , 1981, Cancer.

[19]  F. McKeown,et al.  Oat‐cell carcinoma of the œsophagus , 1952 .

[20]  V. Rusch,et al.  Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  B. Attar,et al.  Small cell carcinoma of the esophagus , 2005, Digestive Diseases and Sciences.

[22]  J. Herman,et al.  Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. , 2005, The Journal of thoracic and cardiovascular surgery.